Several of the cancer immunotherapies under investigation or in clinical use target the
programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling axis. PD-L1 …

Background: Bladder cancer is the ninth most-common cancer worldwide and it is
associated with high morbidity and mortality. Tumor mutational burden (TMB) is an emerging …

Objective POLE exonuclease domain mutations were recently found to occur in a subset of
endometrial carcinomas and result in defective proof-reading function during DNA …

Radiotherapy is one of the cornerstone treatments for endometrial cancer and has
successfully diminished the risk of local recurrences after surgery. However, a considerable …

Aims Endometrial clear cell carcinomas (CCC) constitute fewer than 5% of all carcinomas of
the endometrium. Currently, little is known regarding the genetic basis of endometrial CCC …

Traditionally, gynecological cancers have been classified based on histology. Since
remarkable advancements in next‐generation sequencing technology have enabled the …

Objective Ovarian clear cell carcinoma (OCCC) is an aggressive ovarian cancer with a
higher frequency in Japan and often becomes chemorefractory disease. Reliable genetic …

Endometrial serous carcinoma (ESC) is an aggressive neoplasm mainly seen in older
women. The objective of this study was to refine immunohistochemical (IHC) panels for the …

Purpose Endometrial carcinoma (EC) is a clinically heterogeneous disease characterized by
a number of different histological subtypes, and its heterogeneity may be involved in the …

Objective Somatic POLE mutations have been found in a subset of endometrioid ECs
particularly in FIGO grade 3 tumors while POLD1 mutations are reportedly rare in ECs. While …